FDA Inspection 1167810 — University Of Texas MD Anderson Cancer Center
The FDA completed an inspection of University Of Texas MD Anderson Cancer Center on Mar 24, 2022 in Houston, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 24, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Houston, TX (United States)